Ask AI
ProCE Banner Activity

Shifting the Paradigm in B-Cell ALL: Insights on the Evolving Role of Bispecific Antibodies and CAR T-Cell Strategies

Clinical Thought

Gain insights on recent findings related to the use of bispecific antibodies and CAR T-cell therapy for patients with ALL including new data with blinatumomab, the novel bispecific antibodies surovatamig and CN201 engineered for improved characteristics, and optimizing the implementation of brexu-cel and obe-cel therapy.

Released: August 08, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Faculty Disclosure

Primary Author

Ibrahim Aldoss, MD: consultant/advisor/speaker: AbbVie, Adaptive, Amgen, Autolus, Jazz, Kite, MacroGenics, Pfizer, Syndax, Takeda, Wugen.

Jae H. Park, MD: consultant/advisor/speaker: Adaptive Technologies, AffyImmune, Allogene, Amgen, Artiva Biotherapeutics, Autolus, Be Biopharma, BeiGene, Bright Pharmaceuticals, Bristol Myers Squibb, Caribou Biosciences, Curocell, Galapagos, IN8Bio, Kite, Kura Oncology, Minerva, Novartis, Pfizer, Servier, Synthekine, Takeda.